Belzupacap sarotalocan

BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA) (“Aura” or the “Company”), a clinical-stage biotechnology company developing a potentially transformative first-in-class therapy for patients with ocular cancers, today announced that inducement equity awards (collectively, “Inducement Awards”) were granted to Erica Kratz, Ph.D., Aura’s new Chief Regulatory and Quality Officer, Susan Abu-Absi, Ph.D., Aura’s new Chief Operating Officer, and Julie Person, Aura’s new Chief People Officer, each on September 1, 2026 (the “Grant Date”). The Inducement Awards were approved by the Compensation Committee of the Board of Directors of the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Awards granted to Dr. Kratz consist of (i) non-qualified stock options to purchase an aggregate of 199,115 shares of the Company’s common stock (“Common Stock”) with an exercise price of $7.43 per share, which is equal to the closing price of the Common Stock as reported by Nasdaq on the Grant Date and (ii) restricted stock units (“RSUs”) for 100,885 shares of Common Stock. The Inducement Awards granted to Dr. Abu-Absi consist of (i) non-qualified stock options to purchase an aggregate of 265,487 shares of Common Stock with an exercise price of $7.43 per share, which is equal to the closing price of the Common Stock as reported by Nasdaq on the Grant Date and (ii) RSUs for 134,513 shares of Common Stock. The Inducement Awards granted to Ms. Person consist of (i) non-qualified stock options to purchase an aggregate of 212,389 shares of Common Stock with an exercise price of $7.43 per share, which is equal to the closing price of the Common Stock as reported by Nasdaq on the Grant Date and (ii) RSUs for 107,611 shares of Common Stock. Each of the option awards will vest as follows: 25% shall vest and become exercisable on the first anniversary of the applicable executive’s start date and the remaining 75% shall vest and become exercisable in 36 equal monthly installments thereafter, subject to such executive’s continued service as of each vesting date. The RSU awards will vest as follows: 25% shall vest on September 15, 2027 (the “First Vesting Date”), and 25% shall vest on each of the first year anniversary, second year anniversary, and third year anniversary of the First Vesting Date, subject to each executive’s continued service as of each vesting date. About Aura Biosciences ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); Aura Biosciences is a clinical-stage biotechnology company developing bel-sar, a potentially transformative, first-in-class therapy for patients living with ocular cancers. Bel-sar represents an entirely novel approach to treating ocular cancers via its dual mechanisms of action of acute tumor necrosis and secondary anti-tumor immune activation. The Phase 3 registration study of bel-sar in early choroidal melanoma, the largest patient segment of uveal melanoma, is fully enrolled, and earlier stage studies in metastases to the choroid and cancers of the ocular surface are ongoing. Aura's mission is to improve outcomes for patients living with ocular cancers by delivering a therapy that not only arrests tumor growth but also preserves vision and quality of life. For more information, visit aurabiosciences.com . Follow us on X, @AuraBiosciences, and visit us on LinkedIn. Investor and Media Relations Contact: Alex Dasalla ezstandalone.cmd.push(function () { ezstandalone.showAds(132); }); Head of Investor Relations and Corporate Communications IR@aurabiosciences.com

正文共：990字 预计阅读时间： 4分钟 2026年8月11日，Aura Biosciences在发布二季报的同时宣布了一项重大战略调整：裁减约20%的员工、重组高管团队，并将所有研发资源聚焦于眼科肿瘤学。市场并未因此恐慌，股价反而在短暂下探后小幅上涨，投资者似乎将这轮调整解读为利空出尽。 来源：雪球网 这场变革的伏笔早在几个月前就已埋下。今年4月30日，Aura创始人Elisabet de los Pinos博士卸任CEO及总裁职务。这位2007年创立公司、将其从零打造至纳斯达克上市的生物技术企业家，在Ⅲ期临床完成入组的关键节点选择离场。 接棒的是Natalie Holles，一位拥有超25年行业经验的老将，曾先后担任Audentes Therapeutics（后被安斯泰来收购）和Third Harmonic Bio的CEO。 创始人离任、职业经理人接盘，这在Biotech行业中往往意味着一场战略重塑的开始。 Holles接手时的Aura，管线布局相对分散：核心资产bel-sar同时推进“眼癌之王”脉络膜黑色素瘤Ⅲ期和非肌肉侵入性膀胱癌Ⅰb/Ⅱ期临床。 此前，Aura称bel-sar在非肌肉侵入性膀胱癌中展现了令人鼓舞的早期数据，在低级别疾病患者亚组中，5名患者中有4名实现了临床完全缓解，且Bel-sar曾获得FDA针对该适应症的快速通道（Fast Track）资格认定。可Holles仍果断叫停该适应症的进一步投入，仅保留数据收集至12个月随访结束，美其名曰“为未来战略磋商保留价值创造的可选性”。 这一决策的逻辑不难理解：Biotech的资源永远是有限的。与其在两个战场上分散兵力，不如将弹药集中投向最有希望率先撞线的赛道。bel-sar治疗早期脉络膜黑色素瘤的Ⅲ期CoMpass试验已完成108例患者入组，顶线数据预计2027年下半年读出。若成功，bel-sar有望成为首个获批的早期脉络膜黑色素瘤一线视力保留疗法。这是Aura最接近商业化的资产，不容有失。 伴随战略转向的是高管团队的大换血。新任命的首席运营官、首席监管与质量官、首席人力官三位高管同日到位；而首席财务与商务官、首席法务官及首席技术官三位高管则同步离职。几乎整个核心高管团队的重塑，彰显了新管理层推进变革的决心。 代价同样不菲：20%的裁员预计耗资290万至320万美元，且公司坦承“导致部分长期雇员离职，造成机构知识与专业技能的流失”。但换来的是一份更充裕的现金储备，Aura最新测算显示现有3.238亿美元资金可支撑运营至2029年上半年，较此前延长了约半年。 从创始人离场到新帅挥刀，从管线收缩到高管换血，Aura正在经历一次彻底的自我重塑。市场的温和反应说明投资者认可这一逻辑：与其在多个适应症上浅尝辄止，不如在一个赛道里孤注一掷。当然，战略聚焦只是第一步，bel-sar在2027年的Ⅲ期数据才是真正的大考。届时，这场壮士断腕能否换来新生，答案自会揭晓。 参考资料： 1.https://www.fiercebiotech.com/biotech/aura-lays-20-staff-rejigs-c-suite-amid-rd-refocusing 2.雪球网 3.其他公开资料 封面图来源：药时代团队 告别「传奇」，黄颖的下一程 2026-08-12 13.2亿美元！为了全美仅2500名患者，Jazz为何敢下此血本？ 2026-08-11 剂量翻倍也没用，社恐药「复活」失败！ 2026-08-10 百亿蓝海市场，杀入「粪便疗法」？ 2026-08-08 版权声明/免责声明 本文为原创文章。 本文仅作信息交流之目的，不提供任何商用、医用、投资用建议。 文中图片、视频、字体、音乐等素材或为药时代购买的授权正版作品，或来自微信公共图片库，或取自公司官网/网络，部分素材根据CC0协议使用，版权归拥有者，药时代尽力注明来源。 如有任何问题，请与我们联系。 衷心感谢! 药时代官方网站:www.drugtimes.cn 联系方式: 电话:13651980212 微信:27674131 邮箱:contact@drugtimes.cn 点击查看更多精彩内容！